A Study of Sotorasib in People With Non-Small Cell Lung Cancer

This study tests sotorasib — a targeted drug that blocks a specific cancer-driving mutation called KRAS G12C — as a first treatment option for people with advanced or recurrent non-small cell lung cancer (NSCLC) who have this mutation and have not yet received treatment for their advanced disease. **You may be eligible if...** - You are 18 or older - You have metastatic or recurrent non-small cell lung cancer confirmed by biopsy - Your tumor has the KRAS G12C mutation (from a biopsy or blood test) - You have not yet received treatment for advanced/metastatic disease - You are in reasonably good health (Karnofsky performance score of 70% or higher) **You may NOT be eligible if...** - You have had prior treatment for advanced lung cancer - Your organ function (kidney, liver, blood counts) does not meet minimum requirements - You have active brain metastases Talk to your doctor to see if this trial is right for you.